Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Extended-Spectrum β-Lactamase Producing Enterobacterales in Healthy Community Dogs in Israel

ABSTRACT: Risk factors associated with Extended-Spectrum β-Lactamase Producing Enterobacterales Gut Colonization in Healthy Community Dogs in Israel

PROVIDER: PRJEB46160 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Extended-Spectrum beta-Lactamase-Producing Enterobacterales in Long-Term Care Residents

Project description:Molecular Epidemiology and Risk Factors for Extended-Spectrum β-Lactamase–Producing Enterobacterales in Long-Term Care Residents

| PRJEB56148 | ENA

Sexual transmission of extended-spectrum β-lactamase-producing Enterobacterales: a prospective, single-centre study

Project description:Sexual transmission of extended-spectrum β-lactamase-producing Enterobacterales: a prospective, single-centre study

| PRJEB48102 | ENA

Extended Spectrum Beta-Lactamase-producing Enterobacteriaceae

Project description:Extended Spectrum Beta-Lactamase-producing Enterobacteriaceae Raw sequence reads

| PRJNA476828 | ENA

Prevalence and Molecular Characterization of Extended-Spectrum β-Lactamase Producing <i>Enterobacterales</i> in Healthy Community Dogs in Israel.

Project description:Backgroundantimicrobial resistance is a global problem in human and veterinary medicine. We aimed to investigate the extended spectrum β-lactamase-producing Enterobacterales (ESBL-PE) gut colonization in healthy community dogs in Israel.MethodsRectal swabs were sampled from 145 healthy dogs, enriched, plated on selective plates, sub-cultured to obtain pure cultures, and ESBL production was confirmed. Bacterial species and antibiotic susceptibility profiles were identified. WGS was performed on all of the ESBL-PE isolates and their resistomes were identified in silico. Owners' questionnaires were collected for risk factor analysis.ResultsESBL-PE gut colonization rate was 6.2% (n = 9/145, 95% CI 2.9-11.5). Overall, ten isolates were detected (one dog had two isolates); the main species was Escherichia coli (eight isolates), belonging to diverse phylogenetic groups-B1, A and C. Two isolates were identified as Citrobacter braakii, and C. portucalensis. A phylogenetic analysis indicated that all of the isolates were genetically unrelated and sporadic. The isolates possessed diverse ESBL genes and antibiotic-resistance gene content, suggesting independent ESBL spread. In a multivariable risk factor analysis, coprophagia was identified as a risk factor for ESBL-PE gut colonization (p = 0.048, aOR = 4.408, 95% CI 1.014-19.169).Conclusionshealthy community dogs may be colonized with ESBL-PE MDR strains, some of which were previously reported in humans, that carry wide and diverse resistomes and may serve as a possible source for AMR.

| S-EPMC9404856 | biostudies-literature

Fecal Microbiota Transplantation for Extended-Spectrum Beta Lactamase Carriers.

Project description:Fecal Microbiota Transplantation for Extended-Spectrum Beta Lactamase Carriers.

| PRJEB46779 | ENA

Enterobacterales

Project description:Extended-spectrum Beta-lactamase-producing Enterobacterales in Retail Meat in Singapore

| PRJNA825698 | ENA

Transcriptional alterations of virulence-associated genes in extended spectrum beta-lactamase (ESBL)-producing uropathogenic Escherichia coli during morphologic transitions induced by ineffective antibiotics

Project description:The present study examines changes in global gene expression patterns and in virulence factor-associated genes in an extended spectrum beta-lactamase (ESBL)-producing UPEC (ESBL019) during the morphologic transitions induced by an ineffective antibiotic and in the presence of human primary bladder epithelial cells. The morphological shifts induced by ineffective antibiotics are associated with significant transcriptional virulence alterations in ESBL-producing UPEC, which may affect survival and persistence in the urinary tract.

2017-06-06 | GSE99661 | GEO

Dissemination of extended spectrum β-lactamase-resistant Salmonella spp.

Project description:Investigating the dissemination of extended-spectrum β-lactamase-resistant Salmonella spp. from agricultural to aquatic environments

| PRJEB37713 | ENA

Pharmacokinetic and Pharmacodynamic Analysis of the Oxacephem Antibiotic Flomoxef against Extended-Spectrum β-Lactamase-Producing Enterobacterales from Dogs.

Project description:Flomoxef (FMX) may be a potential alternative to carbapenems for dogs infected with Enterobacterales-producing extended-spectrum β-lactamase (ESBL-E). However, the appropriate dosage of FMX in dogs with ESBL-E infections has yet to be established. This study was carried out to establish appropriate treatment regimens for FMX against ESBL-E infections in dogs using a pharmacokinetics-pharmacodynamics (PK-PD) approach. Five dogs were intravenously administered at a bolus dose of FMX (40 mg/kg body weight). Serum concentrations of FMX were calculated with high-performance liquid chromatography-tandem mass spectrometry, and then applied to determine PK indices based on a non-compartmental model. The cumulative fraction of response (CFR) was estimated based on the dissemination of minimum inhibitory concentrations among wild-type ESBL-E from companion animals. From the results, the dosage regimens of 40 mg/kg every 6 and 8 h were estimated to attain a CFR of >90% for wild-type isolates of ESBL-producing Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis for dogs. By contrast, all regimens had a CFR of <80% for ESBL-producing Enterobacter cloacae. Our results indicated that dosage regimens of 40 mg/kg FMX every 6 and 8 h can be a non-carbapenem treatment for canine infections of ESBL-producing Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, but not for those of ESBL-producing Enterobacter cloacae.

| S-EPMC10816067 | biostudies-literature

Enterobacterales

Project description:Colonization by extended-spectrum-B-lactamase-producing Enterobacterales and bloodstream infection in hematopoietic stem cell transplant recipients

| PRJNA1100951 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data